Neurological Surgery 脳神経外科50巻1号

2022年01月発行

特集 Precision Medicine—個別化医療を目指した遺伝子診断と新治療の知見 Ⅱ良性脳腫瘍

神経鞘腫—治療標的分子の検討

著者： 田村亮太¹ 戸田正博¹

所属機関： ¹慶應義塾大学医学部脳神経外科

ページ範囲：P.162 - P.170

Point
・孤発性およびNF2神経鞘腫の生物学的特性を考慮した治療戦略を検討する必要がある．
・特にNF2神経鞘腫に対しては，VEGF/VEGFR経路を標的とした治療がさらに発展し得る．
・その他，SH3PXD2AとHTRA1の融合遺伝子やPI3K/Akt/mTOR経路を標的とした治療も注目される．

参考文献

1）Pandrangi VC, et al：An update on epidemiology and management trends of vestibular schwannomas. Otol Neurotol 41：411-417, 2020

2）Sun S, Liu A：Long-term follow-up studies of Gamma Knife surgery with a low margin dose for vestibular schwannoma. J Neurosurg 117 Suppl：57-62, 2012

3）Tamura R：Current understanding of neurofibromatosis type 1, 2, and schwannomatosis. Int J Mol Sci 22：5850, 2021

4）Behr R, et al：New outcomes with auditory brainstem implants in NF2 patients. Otol Neurotol 35：1844-1851, 2014

5）Lee JD, et al：Genetic and epigenetic alterations of the NF2 gene in sporadic vestibular schwannomas. PLoS One 7：e30418, 2012

6）Teranishi Y, et al：Targeted deep sequencing of DNA from multiple tissue types improves the diagnostic rate and reveals a highly diverse phenotype of mosaic neurofibromatosis type 2. J Med Genet 58：701-711, 2021

7）Petrilli AM, Fernández-Valle C：Role of merlin/NF2 inactivation in tumor biology. Oncogene 35：537-548, 2016

8）Agnihotri S, et al：The genomic landscape of schwannoma. Nat Genet 48：1339-1348, 2016

9）Acevedo LM, et al：Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood 111：2674-2680, 2008

10）Uesaka T, et al：Expression of VEGF and its receptor genes in intracranial schwannomas. J Neurooncol 83：259-266, 2007

11）Tamura R, et al：Quantitative assessment and clinical relevance of VEGFRs-positive tumor cells in refractory brain tumors. Exp Mol Pathol 114：104408, 2020

12）Plotkin SR, et al：Multicenter, prospective, phase Ⅱ and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma. J Clin Oncol 37：3446-3454, 2019

13）Fujii M, et al：Bevacizumab therapy of neurofibromatosis type 2 associated vestibular schwannoma in Japanese patients. Neurol Med Chir（Tokyo）60：75-82, 2020

14）Tamura R, et al：Author Correction：a VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2. Nat Commun 11：2028, 2020

15）Karajannis MA, et al：Sustained imaging response and hearing preservation with low-dose bevacizumab in sporadic vestibular schwannoma. Neuro Oncol 21：822-824, 2019

16）Ahmad ZK, et al：ErbB expression, activation, and inhibition with lapatinib and tyrphostin（AG825）in human vestibular schwannomas. Otol Neurotol 32：841-847, 2011

17）Doherty JK, et al：ErbB and Nrg：potential molecular targets for vestibular schwannoma pharmacotherapy. Otol Neurotol 29：50-57, 2008

18）Ammoun S, et al：ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol 12：834-843, 2010

19）Plotkin SR, et al：Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol 31：1135-1143, 2010

20）Mukherjee J, et al：Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec（imatinib mesylate）. Cancer Res 69：5099-5107, 2009

21）Yener U, et al：Assessment of antiangiogenic effect of imatinib mesylate on vestibular schwannoma tumors using in vivo corneal angiogenesis assay. J Neurosurg 117：697-704, 2012

22）Ammoun S, et al：Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. Neuro Oncol 13：759-766, 2011

23）Konstorum A, Lowengrub JS：Activation of the HGF/c-Met axis in the tumor microenvironment：a multispecies model. J Theor Biol 439：86-99, 2018

24）Dilwali S, et al：Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells. Cancer Biol Ther 16：170-175, 2015

25）Hu SY, et al：Hepatocyte growth factor protects endothelial cells against gamma ray irradiation-induced damage. Acta Pharmacol Sin 30：1415-1420, 2009

26）Zhao Y, et al：Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proc Natl Acad Sci U S A 115：E2077-E2084, 2018

27）Welling DB, et al：cDNA microarray analysis of vestibular schwannomas. Otol Neurotol 23：736-748, 2002

28）Lee TX, et al：Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. Eur J Cancer 45：1709-1720, 2009

29）Bush ML, et al：AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro Oncol 13：983-999, 2011

30）James MF, et al：Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types. Mol Cancer Res 10：649-659, 2012

31）Lane HA, et al：mTOR inhibitor RAD001（everolimus）has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 15：1612-1622, 2009

32）Goutagny S, et al：Phase Ⅱ study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neurooncol 122：313-320, 2015

33）Karajannis MA, et al：Phase Ⅱ study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol 16：292-297, 2014

Ga］-Pentixafor PET/CT for CXCR4-mediated imaging of vestibular schwannomas. Front Oncol 9：503, 2019

35）Breun M, et al：CXCR4：a new player in vestibular schwannoma pathogenesis. Oncotarget 9：9940-9950, 2018

36）Hannan CJ, et al：The inflammatory microenvironment in vestibular schwannoma. Neurooncol Adv 2：vdaa023, 2020

37）Fujioka M, et al：Inflammatory and immune responses in the cochlea：potential therapeutic targets for sensorineural hearing loss. Front Pharmacol 5：287, 2014

38）Tamura R, et al：Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas. J Neurooncol 146：265-273, 2020

39）Tamura R, et al：The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment：perspectives for therapeutic implications. Med Oncol 37：2, 2019

40）Li Z, et al：TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant schwannomas. Tumour Biol 39：1010428317698352, 2017

41）Wang S, et al：Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J Neurooncol 138：183-190, 2018

42）Nakanishi M, Rosenberg DW：Multifaceted roles of PGE2 in inflammation and cancer. Semin Immunopathol 35：123-137, 2013

43）Hong B, et al：Cyclooxygenase-2 supports tumor proliferation in vestibular schwannomas. Neurosurgery 68：1112-1117, 2011

44）Kandathil CK, et al：Aspirin intake correlates with halted growth of sporadic vestibular schwannoma in vivo. Otol Neurotol 35：353-357, 2014

45）MacKeith S, et al：Aspirin does not prevent growth of vestibular schwannomas：a case-control study. Laryngoscope 128：2139-2144, 2018

46）Whitesell L, Lindquist SL：HSP90 and the chaperoning of cancer. Nat Rev Cancer 5：761-772, 2005

47）Tanaka K, et al：Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2. Clin Cancer Res 19：3856-3870, 2013

48）Ren Y, et al：Gene therapy for human sensorineural hearing loss. Front Cell Neurosci 13：323, 2019

49）Prabhakar S, et al：Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1. Hum Gene Ther 24：152-162, 2013

50）Ahmed SG, et al：Gene therapy with apoptosis-associated speck-like protein, a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo. Neuro Oncol 21：854-866, 2019